Back
 

Group Leader/s

Head of lab
 

intro

The “Cell-Biomaterial Recognition Lab” explores the interactions between cells and biomaterials with applications for bone tissue repair. Biomaterials under study comprise metallic materials, as are cobalt-chromium alloys with high carbon content and biodegradable magnesium-base materials, and ceramic materials as are the hydroxyapatites.

Different cellular and molecular approaches and tools are carried out to understand the biological response that takes place as a consequence of the interaction with the material with the final goal to select materials biocompatibles with minimal adverse effects, being one of the most relevant complications the osteolysis produced by metallic particles and ions. The metallic material degradation (particles and ions) produces as a final consequence the loosening of the implanted prostheses that suppose an inconvenient for patients with an economical cost that affect the sustainability of the public health system.   

Our biological studies on surface-modified cobalt-chromium alloys with high carbon content, with a new strategy to minimize wear process ameliorating lubrication, and magnesium-based materials with a biodegradation kinetic rate synchronized with bone tissue regeneration and functionalized hydroxyapatites with different proteins that enhances activities of other peptides involved in bone tissue growth, will allow to get better implants for bone tissue repair.

 

 

Cryosem images of 3D osteoblasts MC3T3-E1 cell cultures in CellCeram scaffolds. Panel A: scaffold in the absence of cells and particles used as control for 3D osteoblasts cell cultures (scale bar: 1 mm); Panel B: scaffold incubated with CoCr particles. Particles with round shape appear inside scaffold labeled with a black arrow (scale bar: 20 μm); Panel C: osteoblasts MC3T3-E1 cells cultured on scaffolds in presence of 0.5 mg/ml of CoCr particles (scale bar: 50 μm). Extended cells´filopodia are observed on scaffold surface; Panel D: detail of osteoblasts cell cultured on scaffold in presence of 0.5 mg/ml of CoCr particles (scale bar: 20 μm)
Cryosem images of 3D osteoblasts MC3T3-E1 cell cultures in CellCeram scaffolds. Panel A: scaffold in the absence of cells and particles used as control for 3D osteoblasts cell cultures (scale bar: 1 mm); Panel B: scaffold incubated with CoCr particles. Particles with round shape appear inside scaffold labeled with a black arrow (scale bar: 20 mm); Panel C: osteoblasts MC3T3-E1 cells cultured on scaffolds in presence of 0.5 mg/ml of CoCr particles (scale bar: 50 mm). Extended cells´ filopodia are observed on scaffold surface; Panel D: detail of osteoblasts cell cultured on scaffold in presence of 0.5 mg/ml of CoCr particles (scale bar: 20 mm).
 

Research lines

View Current View Past
 

Members

Staff Scientists
Rosa María Lozano Puerto
Visitors
Luna Sanchez Lopez
Lab team of Cell-Biomaterial Recognition
 

Selected Publications

S.E. Benito-Santiago, R.M. Lozano-Puerto, E. Onofre-Bustamante  [2023]. “Synthesis and characterization of CeO2 coatings on AZ31 alloy for corrosion protection and in-vitro biocompatibility of MC3T3-E1 pre-osteoblasts”. Metals , 13(4), 653 (2023) https://doi.org/10.3390/met13040653

Luna Sánchez-López, Noelia Ropero de Torres, Belén Chico, Natalia Soledad Fagali, Vivian de los Ríos, María Lorenza Escudero, María Cristina García-Alonso, Rosa Mª Lozano.  [2023]. “Effect of wear-corrosion of reduced graphene oxide functionalized with hyaluronic acid on inflammatory and proteomic response of J774A.1 macrophages”. Metals 13, 598-626 (2023) https://doi.org/ 10.3390/met13030598

MC. García-Alonso, B. Chico, RM. Lozano, ML. Escudero  [2023]. “Tribocorrosion behavior of graphene-based solid lubricants biofunctionalized with hyaluronic acid on CoCr surfaces”. Tribology International 183, 108420-108427 (2023) https://doi.org/10.1016/j.triboint.2023.108420

Sánchez-López, L.; Chico, B.; Llorente, I.; Escudero M.L.; Lozano, R.M.; García- Alonso, M.C.  [2022]. “Covalent immobilization of graphene oxide on biomedical grade CoCr alloy by an improved multilayer system assembly via Silane/GO bonding”.Materials Chemistry and Physics 287, 126296 (2022) doi.org/10.1016/j.matchemphys.2022.126296

Chico, B.; Pérez-Maceda, B.T.; San-José, S.; Escudero, M.L.; García-Alonso, M.C.; Lozano, R.M.  [2022]. “Wettability, Corrosion Resistance, and Osteoblast Response to Reduced Graphene Oxide on CoCr Functionalized with Hyaluronic Acid”. Materials, 15, 2693. (2022) Doi: ma15072693

Aguado-Henche, S.; Escudero, M.L.; García-Alonso, M.C.; Lozano-Puerto, R.M.; Clemente de Arriba, C.  [2022]. “Biological Responses in the Blood and Organs of Rats to Intraperitoneal Inoculation of Graphene and Graphene Oxide”. Materials, 15, 2898 (2022) Doi: ma15082898

Chico, B., Pérez-Maceda, B.T., San José, S., Escudero, M.L., García-Alonso, M.C. y Lozano, R.M.  [2021]. “Corrosion behaviour and J774A.1 macrophage response to hyaluronic acid functionalization of electrochemically reduced graphene oxide on biomedical grade CoCr” Metals 11, 1078-1092 (2021) doi:103390/met11071078

Natalia S. Fagali, Marcos A. Madrid, Blanca T. Pérez Maceda, María E. López Fernández, Rosa M. Lozano Puerto, Mónica Fernández Lorenzo de Mele  [2020]. “Effect of degradation products of iron-bioresorbable implants on the physiological behavior of macrophages in vitro”. Metallomics (2020) DOI: 10.1039/D0MT00151A

M.L. Escudero, I. Llorente, B.T. Pérez-Maceda, S. San José-Pinilla, L. Sánchez-López, R.M. Lozano, S. Aguado-Henche, C. Clemente de Arriba, M.A. Alobera-Gracia, M.C. García-Alonso  [2020]. “Electrochemically reduced graphene oxide on CoCr biomedical alloy: Characterization, macrophage biocompatibility and hemocompatibility in rats with graphene and graphene oxide”Materials Science & Engineering C 109 (2020) 110522

Pérez-Maceda, Blanca; López-Fernández, María Encarnación; Diaz, Ivan; Kavanaugh, Aaron; Billi, Fabrizio; Escudero, María; Garcia-Alonso, María Cristina; Lozano, Rosa M.  [2018]. " Macrophage biocompatibility of CoCr wear particles produced under polarization in hyaluronic acid aqueous solution”. Materials 11, 756, (2018). doi:10.3390/ma11050756

Alvarez F., Lozano Puerto R.M., Pérez-Maceda B., Grillo C.A., and Fernández Lorenzo de Mele M.  [2016]. Time-Lapse Evaluation of Interactions Between Biodegradable Mg Particles and Cells. Microsc. Microanal. 22, 1–12.

Lozano RM*, Pérez-Maceda BT, Carboneras M, Onofre-Bustamante E, García-Alonso MC, Escudero ML  [2013]. Response of MC3T3-E1 osteoblasts, L929 fibroblasts and J774 macrophages to fluoride surface-modified AZ31 magnesium alloy. Journal of Biomedical Materials Research: Part A. 101: 2753-2762.

All Publications
 

Funding

Biocompatibility and inflammatory reponse involve in periprosthesic osteolysis of new metallic materials with graphitic solid lubricants. Reference: MAT2015-67750-C3-2-R. (2016-2018). Funding agency: Ministerio de Economía y Competitividad. IP: Rosa Mª Lozano Puerto y Blanca T. Pérez Maceda

Cell biocompatibility of metallic wears debris derived from the synergic process of wear and corrosion of the pair metal on metal of a CoCr alloy. Reference: MAT2011-29152-C02-02. Funding agency:  Ministerio de Ciencia e Innovación. (2012-2014). IP: Rosa Mª Lozano Puerto

Bioceramic scaffolds for tissue engineering. Reference: CAM  S2009/MAT1472. (2010-2014). Funding agency: Comunidad de Madrid. IP: María Vallet Regí. Rosa Mª Lozano participates as associated member to Dra. María Teresa Portolés Pérez lab. at the Universidad Complutense Madrid.

In vitro and in vivo studies of the interaction of cell and new surfaces of magnesium-based metallic biomaterials. Reference: MAT2008-06719-C03-02/MAT. (2009-2011). Funding agency: Ministerio de Ciencia e Innovación. IP: Rosa Mª Lozano Puerto

 

 

More info

Patents:

Buchanan, B. B., Lozano, R. M., Yee, B. C., Kobrehel, K., Frick, O. L. y Ermel, R. W.Neutralization of food allergens by thioredoxin. WO9612799 (2/5/1996); US5792506 (11/8/1998); US6190723 (20/2/2001)

Buchanan, B. B., del Val, G., Lozano, R. M., Jiao, J., Wong, J.H. and Yee, B.C. Increasing the digestibility of food proteins by thioredoxin reduction.WO9920122 (29/4/1999); US5952034 (14/9/1999); US6838113 (4/1/2005)

Buchanan, B.B., del Val, G., Lozano, R.M., Wong, J.H., Yee, B.C and Frick, O.L. Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin. WO0044781 (3/8/2000); US7,074,900 (11/07/2006)

Buchanan, B.B., Yee, B.C, Kobrehel, K., Lozano, R.M, Wong, J.H., Jiao, J and Sungho, S. Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods and for inactivating snake, bee and scorpion toxins.US6113951 (5/9/2000); US6114504 (5/9/2000); US6600021 (29/7/2003); US2003215542 (20/11/2003); EPO0863154 (9/9/1998)

Giménez Gallego, G., Valverde López, S, Lozano Puerto, R.M. and Cuevas, P. Pharmaceutical compositions containing sulphonic acid derivatives. WO2004078704. Nº Patente OEPM: 2214968 (26/10/2005). Transferida al laboratorio farmacéutico ITALFARMACO S.A.

Cuevas Sánchez , P., Romero Garrido, A., Giménez-Gallego, G. Valverde López, S. and Lozano Puerto, R.M. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis. WO2005/077352. US patent application: 11/506,489 (16/08/2006). Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Valverde López, S., Romero Garrido, A. and Lozano Puerto, R.M. Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis. WO2008/020025 (21-02-2008) PCT/EP2007/058438. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Valverde López, S., Romero Garrido, A. and Lozano Puerto, R.M. 2,5-dihydroxybenzene derivatives for the treatment dermatitis. WO2008/020026 (21-02-2008 )PCT/EP2007/058439. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman I., Angulo Frutos, J., Valverde López, S., Romero Garrido, A. and Lozano Puerto, R.M. 2,5-dihydroxybenzene compounds for the treatment of rosacea. WO2008/020028 (21-02-2008) PCT/EP2007/058441. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman I., Angulo Frutos, J., Valverde López, S., Romero Garrido, A. and Lozano Puerto, R.M. 2,5-dihydroxybenzene compounds for the treatment of psoriasis.WO2008/020030 (21-02-2008) PCT/EP2007/058443. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Lozano Puerto, R.M, Romero Garrido, A and Valverde López, S. Use of 2,5-dihydroxybenzene derivatives for the treatment of angiogenic diseases. WO2008/020031 (21-02-2008) PCT/EP2007/058444. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Lozano Puerto, R.M, Romero Garrido, A and Valverde López, S. Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases. WO2008/020032 (21-02-2008) PCT/EP2007/058445. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Lozano Puerto, R.M, Romero Garrido, A and Valverde López, S. Use of 2,5-dihydroxybenzene sulfonic acid derivatives for the treatment of arthritis and pain. WO2008/020033 (21-02-2008) PCT/EP2007/058446. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Lozano Puerto, R.M, Romero Garrido, A and Valverde López, S. Use of 2,5-dihydroxybenzene sulfonic acid compounds for treatment of hemangiomas or hemangioblastomas. WO2008/020034 (21-02-2008) PCT/EP2007/058447. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Lozano Puerto, R.M, Romero Garrido, A., Valverde López, S. and García Gómez, I. Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating obesity, hirsutism, hypertricosis and viral warts. WO2008/020037(21-02-2008)PCT/EP2007/058451.Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Lozano Puerto, R.M, Romero Garrido, A and Valverde López, S. 2,5-dihydroxybenzene sulfonic acid compounds for treating cancers and hematological dyscrasias.WO2008/020039(21-02-2008)PCT/EP2007/058453. Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J., Lozano Puerto, R.M, Romero Garrido, A and Valverde López, S. 2,5-dihydroxybenzene sulfonic acid derivatives for the treatment of fibrosis. WO2008/020040(21-02-2008)PCT/EP2007/058454.Transferida a ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman I., Angulo Frutos, J., Valverde López, S., Romero Garrido, A. and Lozano Puerto, R.M. 2,5-dihydroxybenzene compounds for the treatment of skin cancer. Patent Number: 8101660. 24 Enero 2012. WO patent application: 2008/020027 Pub. Date:21-02-2008 PCT/EP2007/058440. Transferida a Amderma Pharmaceuticals LLC (Bridgewater, NJ, USA) Antes ACTION MEDICINES, S.L.

Cuevas Sánchez , P., Giménez-Gallego, G., Sáenz de Tejada Gorman, I., Angulo Frutos, J.,Moreno Nuncio, F.J., Rivas López, L.I. Fernández Jaen, T.F., Lozano Puerto, R.M, Romero Garrido, A and Valverde López, S. Use of 2,5-dihydroxybenzene sulfonic acid derivatives for tissue reactive diseases. Patent Number: EP2056805 B1. Fecha patente: 25/5/2011. WO patent application: 2008/020042.Pub.Date:21-02-2008 PCT/EP2007/058456. Transferida a Amderma Pharmaceuticals LLC (Bridgewater, NJ, USA) Antes ACTION MEDICINES, S.L.